Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 12/20 | 0.49 |
| ▸ | GCGR | P47871 | 4/20 | 0.46 |
| ▸ | GLP1R | P43220 | 1/20 | 0.46 |
| ▸ | GIPR | P48546 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720065 | 0.93 | DGAT1 (0.44) | GCGGCGRGLP1RGIPRDGAT1 | |
| SCHEMBL720050 | 0.89 | RCE1 (0.46) | DGAT1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL720988 | 0.89 | DGAT1 (0.41) | GCGGCGRGLP1RGIPRDGAT1 | |
| SCHEMBL721158 | 0.88 | GCG (0.39) | GCGDGAT1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL717935 | 0.88 | GCG (0.51) | GCGGCGRGLP1RGIPR | |
| SCHEMBL717909 | 0.88 | DGAT1 (0.42) | GCGGCGRGLP1RGIPRDGAT1 | |
| SCHEMBL717738 | 0.87 | GCGR (0.49) | GCGGCGRGLP1RGIPR | |
| SCHEMBL720758 | 0.87 | DGAT1 (0.41) | GCGDGAT1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL717381 | 0.87 | RAB9A (0.42) | DGAT1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL719392 | 0.86 | GCG (0.51) | GCGGCGRGLP1RGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885GCGR 90/4885GLP1R 5/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885GCGR 90/4885GLP1R 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.